Login to Your Account



Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy

By Marie Powers
Staff Writer

Tuesday, November 22, 2011

Thanksgiving came early for Pharmasset Inc. with the news that Gilead Sciences Inc. will gobble it up in a deal valued at $11 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription